Lunai Bioworks (NASDAQ:LNAI) Posts Quarterly Earnings Results

Lunai Bioworks (NASDAQ:LNAI) issued its quarterly earnings data on Tuesday. The company reported ($0.44) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.03 million during the quarter.

Lunai Bioworks Stock Down 13.4%

NASDAQ:LNAI opened at $0.89 on Thursday. The stock has a market capitalization of $4.05 million, a price-to-earnings ratio of -2.23 and a beta of 0.37. Lunai Bioworks has a 52 week low of $0.88 and a 52 week high of $13.28. The firm has a 50 day moving average of $2.02 and a 200 day moving average of $2.49.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Lunai Bioworks in a report on Friday, October 2nd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.